HYDERABAD: Covid-19 vaccine Sputnik V was approved by the Indian health agency ICMR for emergency use in India. In May 2021, it was procured by Dr Reddy’s Laboratories Ltd for the Indian market. Now, after 3 months, thanks to the efforts of the Russian Direct Investment Fund(RDIF) and Dr Reddy’ Laboratories Ltd, Sputnik V will be indigenously produced in India from the current month.
“We are working closely with our partners in India for manufacturing readiness. We expect that locally manufactured doses are likely to be available from the September-October period,” told by spokesperson of Hyderabad-based Dr Reddy’s Laboratories.
“We have received 31.5 lakh doses of component 1 and 4.5 lakh doses of component 2 of the Sputnik V vaccine in India so far. We are working closely with the RDIF to ramp up supplies,” said the spokesperson.
India’s Serum Institute Of India is the largest producer of vaccines in the world and in July, RDIF had announced that collaboration with Serum Institute of India would be done in which 300 million doses of vaccine would be produced in India. Now India will become hub for Sputnik V production and it will fulfill the requirements of India as well as the other countries throughout the globe where the vaccines are going to be supplied, hinted by the RDIF.
In India, currently two vaccines are being produced and administered indigenously, which are Covaxin and Covidshield, with Sputnik V will joining them soon when it comes to indigenous production in India.